AIMS: To assess the effect of prognostic factors on overall survival from node negative breast cancer. METHODS: Information was collected on 1138 node negative breast cancer patients in the Auckland region, diagnosed between 1976 and 1985. Prognostic variables investigated included oestrogen (ER) and progesterone (PR) receptor status, tumour grade, tumour size, body mass index, lactation history and parity. The effects of these variables on overall survival were assessed separately in pre and postmenopausal groups. RESULTS: Over a median follow up time of 10.2 years, improved survival was seen in premenopausal women with PR+ status (p = 0.0007), ER+ status (p = 0.03), positive lactational history (p = 0.03) and low tumour grade (p = 0.04). In postmenopausal women, only ER+ status (p = 0.01) and PR+ status (p = 0.02) were associated with improved survival. Multivariate analysis suggested that positive PR status combined with tumour size provided the best prognostic discrimination in premenopausal women, whereas ER status was the dominant prognostic variable in postmenopausal patients. CONCLUSIONS: For premenopausal node negative women, progesterone receptor status, considered either alone, or together with tumour size, provides the best prognostic prediction of survival. By comparison, oestrogen receptor status is the most important predictor of overall survival in postmenopausal women.
AIMS: To assess the effect of prognostic factors on overall survival from node negative breast cancer. METHODS: Information was collected on 1138 node negative breast cancerpatients in the Auckland region, diagnosed between 1976 and 1985. Prognostic variables investigated included oestrogen (ER) and progesterone (PR) receptor status, tumour grade, tumour size, body mass index, lactation history and parity. The effects of these variables on overall survival were assessed separately in pre and postmenopausal groups. RESULTS: Over a median follow up time of 10.2 years, improved survival was seen in premenopausal women with PR+ status (p = 0.0007), ER+ status (p = 0.03), positive lactational history (p = 0.03) and low tumour grade (p = 0.04). In postmenopausal women, only ER+ status (p = 0.01) and PR+ status (p = 0.02) were associated with improved survival. Multivariate analysis suggested that positive PR status combined with tumour size provided the best prognostic discrimination in premenopausal women, whereas ER status was the dominant prognostic variable in postmenopausal patients. CONCLUSIONS: For premenopausal node negative women, progesterone receptor status, considered either alone, or together with tumour size, provides the best prognostic prediction of survival. By comparison, oestrogen receptor status is the most important predictor of overall survival in postmenopausal women.
Authors: Anne McTiernan; Kumar B Rajan; Shelley S Tworoger; Melinda Irwin; Leslie Bernstein; Richard Baumgartner; Frank Gilliland; Frank Z Stanczyk; Yutaka Yasui; Rachel Ballard-Barbash Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544
Authors: Anna Morra; Audrey Y Jung; Marjanka K Schmidt; Jenny Chang-Claude; Sabine Behrens; Renske Keeman; Thomas U Ahearn; Hoda Anton-Culver; Volker Arndt; Annelie Augustinsson; Päivi K Auvinen; Laura E Beane Freeman; Heiko Becher; Matthias W Beckmann; Carl Blomqvist; Stig E Bojesen; Manjeet K Bolla; Hermann Brenner; Ignacio Briceno; Sara Y Brucker; Nicola J Camp; Daniele Campa; Federico Canzian; Jose E Castelao; Stephen J Chanock; Ji-Yeob Choi; Christine L Clarke; Fergus J Couch; Angela Cox; Simon S Cross; Kamila Czene; Thilo Dörk; Alison M Dunning; Miriam Dwek; Douglas F Easton; Diana M Eccles; Kathleen M Egan; D Gareth Evans; Peter A Fasching; Henrik Flyger; Manuela Gago-Dominguez; Susan M Gapstur; José A García-Sáenz; Mia M Gaudet; Graham G Giles; Mervi Grip; Pascal Guénel; Christopher A Haiman; Niclas Håkansson; Per Hall; Ute Hamann; Sileny N Han; Steven N Hart; Mikael Hartman; Jane S Heyworth; Reiner Hoppe; John L Hopper; David J Hunter; Hidemi Ito; Agnes Jager; Milena Jakimovska; Anna Jakubowska; Wolfgang Janni; Rudolf Kaaks; Daehee Kang; Pooja Middha Kapoor; Cari M Kitahara; Stella Koutros; Peter Kraft; Vessela N Kristensen; James V Lacey; Diether Lambrechts; Loic Le Marchand; Jingmei Li; Annika Lindblom; Jan Lubiński; Michael Lush; Arto Mannermaa; Mehdi Manoochehri; Sara Margolin; Shivaani Mariapun; Keitaro Matsuo; Dimitrios Mavroudis; Roger L Milne; Taru A Muranen; William G Newman; Dong-Young Noh; Børge G Nordestgaard; Nadia Obi; Andrew F Olshan; Håkan Olsson; Tjoung-Won Park-Simon; Christos Petridis; Paul D P Pharoah; Dijana Plaseska-Karanfilska; Nadege Presneau; Muhammad U Rashid; Gad Rennert; Hedy S Rennert; Valerie Rhenius; Atocha Romero; Emmanouil Saloustros; Elinor J Sawyer; Andreas Schneeweiss; Lukas Schwentner; Christopher Scott; Mitul Shah; Chen-Yang Shen; Xiao-Ou Shu; Melissa C Southey; Daniel O Stram; Rulla M Tamimi; William Tapper; Rob A E M Tollenaar; Ian Tomlinson; Diana Torres; Melissa A Troester; Thérèse Truong; Celine M Vachon; Qin Wang; Sophia S Wang; Justin A Williams; Robert Winqvist; Alicja Wolk; Anna H Wu; Keun-Young Yoo; Jyh-Cherng Yu; Wei Zheng; Argyrios Ziogas; Xiaohong R Yang; A Heather Eliassen; Michelle D Holmes; Montserrat García-Closas; Soo Hwang Teo Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-01-26 Impact factor: 4.090
Authors: D S M Chan; A R Vieira; D Aune; E V Bandera; D C Greenwood; A McTiernan; D Navarro Rosenblatt; I Thune; R Vieira; T Norat Journal: Ann Oncol Date: 2014-04-27 Impact factor: 32.976